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Summary
SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients.
Since surgical patients are already at higher risk of venous thromboembolism than general populations, this
study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of
venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre,
prospective cohort study of elective and emergency patients undergoing surgery during October 2020.
Patients from all surgical specialties were included. The primary outcome measure was venous
thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 days of surgery. SARS-CoV-2
diagnosis was defined as peri-operative (7 days before to 30 days after surgery); recent (1–6 weeks before
surgery); previous (≥7 weeks before surgery); or none. Information on prophylaxis regimens or pre-operative
anti-coagulation for baseline comorbidities was not available. Postoperative venous thromboembolism rate
was 0.5% (666/123,591) in patients without SARS-CoV-2; 2.2% (50/2317) in patients with peri-operative SARS-
CoV-2; 1.6% (15/953) in patients with recent SARS-CoV-2; and 1.0% (11/1148) in patients with previous SARS-
CoV-2. After adjustment for confounding factors, patients with peri-operative (adjusted odds ratio 1.5 (95%CI
1.1–2.0)) and recent SARS-CoV-2 (1.9 (95%CI 1.2–3.3)) remained at higher risk of venous thromboembolism,
with a borderline finding in previous SARS-CoV-2 (1.7 (95%CI 0.9–3.0)). Overall, venous thromboembolism was
independently associated with 30-day mortality (5.4 (95%CI 4.3–6.7)). In patients with SARS-CoV-2, mortality
without venous thromboembolismwas 7.4% (319/4342) andwith venous thromboembolismwas 40.8% (31/76).
Patients undergoing surgery with peri-operative or recent SARS-CoV-2 appear to be at increased risk of
postoperative venous thromboembolism compared with patients with no history of SARS-CoV-2 infection.
Optimal venous thromboembolism prophylaxis and treatment are unknown in this cohort of patients, and these
data should be interpreted accordingly.
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Introduction
Patients hospitalised with COVID-19 have a high risk of
venous thromboembolism (VTE), with an estimated
incidence between 9% and 26% [1–5] despite
pharmacological prophylaxis, and as high as 21–31% in
patients within critical care settings [1, 2, 4, 6]. As a result,
preliminary mixed guidance has been issued, with some
suggesting no change in practice, while others suggesting
that increased doses and duration of pharmacological
prophylaxis may be beneficial [7, 8]. However, such
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regimens are associated with serious bleeding risks [9].
Determining the optimal VTE prophylactic regimen for
patients with moderate and severe COVID-19 is an active
area of research (e.g. REMAP-CAP, ACTIV-4a, ATTACC
Investigators, pre-print, https://doi.org/10.1101/2021.03.
10.21252749) [10].
The incidence of VTE in surgical patients infected with
SARS-CoV-2 is not well known. Most patients undergoing
surgery already have risk-factors for VTE, including
immobility, surgical wounds and systematic inflammation.
The addition of SARS-CoV-2 infection may further increase
this risk, but the extent and impact are unknown, and large
scale, prospective patient-level data are lacking. Surgical
patients may also carry asymptomatic SARS-CoV-2
infections, and whether this contributes to excess risk is also
unknown.
Robust evidence is needed to enable clinicians and
policymakers to minimise VTE risk in patients with SARS-
CoV-2 infection. Ideally, such evidencewould stratify the risk
of VTE against both the duration of time between infection
and surgery and presence or absence of symptoms. This
study aimed to determine the VTE rate in patients with
SARS-CoV-2 infection, stratifiedby current or prior infection.
Methods
This study was conducted according to guidelines set by the
strengthening the reporting of observational studies in
epidemiology (STROBE) statement for observational
studies [11]. This was a planned sub-study and analysis from
a prospective, international, multicentre cohort study of
patients undergoing surgery during October 2020. Data
were collected as part of this larger study in the same time
frame. This prior study focused on overall 30-day mortality
with specific reporting on pulmonary complications. The
methods and findings of this study were published
previously [12].
Hospitals providing surgery from any surgical specialty
were eligible for participation. Study approvals for
participating hospitals were secured in line with local and
national regulations before entry into the study. Local
investigators were required to confirm that all mandatory
approvals were in place before data collection could begin.
The study protocol was either registered as a clinical audit
with institutional review or a research study obtaining
ethical committee approval depending on local and
national requirements. Informed patient consent was
obtained if this was necessary to comply with local or
national regulations. In the UK, this study was registered as a
clinical audit in the central co-ordinating site and registered
as either an audit or service evaluation at other recruiting
institutions. Therefore, consent was not mandated from
individual patients. Data were collected online and stored
on a secure server running the Research Electronic Data
Capture (REDCap, Vanderbilt University, Nashville, TN,
USA) web application [13], based at the University of
Birmingham, UK. Hospitals registered their interest to
participate based on one or more surgical specialties.
Participating specialties then collected data on consecutive
patients who underwent surgery within their department
during one or more pre-selected weeks between 5October
and 1 November 2020, with a 30-day postoperative follow-
up period. No changes were made to local patient care
protocols during the course of this study. Only anonymised,
routine clinical datawere collected.
Adult patients, aged 18 y and over, undergoing
elective or emergency surgery for any indication, from any
specialty, were eligible. As VTE events are very rare in
patients aged <18 y, these patients were not included from
this current analysis. Surgery was defined as any procedure
routinely performed in an operating theatre by a surgeon. A
list of excluded procedures can be found in online
Supporting Information Table S1.
Baseline patient characteristics included age, ASA
physical status and smoking status. Age was collected as a
categorical variable in deciles of years and categorised into
three groups for analysis: 18–49 y; 50–69 y; and ≥70 y. The
ASA physical status was dichotomised to 1–2 or 3–5.
Patients were identified as smokers if they were current
smokers or had smoked in the six weeks before surgery.
Data collected on pre-existing medical conditions included
respiratory comorbidities (asthma; chronic obstructive
pulmonary disease); congestive cardiac failure; cerebro-
vascular disease; chronic kidney disease; and ischaemic
heart disease. Indications for surgery were classified as:
benign disease; cancer; obstetrics; or trauma. Operative
variables included urgency of surgery (elective or
emergency); type of anaesthesia (local/regional or general);
and grade of surgery (minor or major). National income was
based on the World Bank’s classification for each
participating country [14].
A positive SARS-CoV-2 diagnosis was based on a
patient having one or more of the following: a positive
reverse transcriptase-polymerase chain reaction (RT-PCR)
nasopharyngeal swab; a positive rapid antigen test; chest
computed tomography (CT) scan showing changes in
keeping with locally implemented protocols that indicate
SARS-CoV-2 infection; positive immunoglobulin G or
immunoglobulin M antibody test; or clinical diagnosis of
symptoms in keeping with COVID-19 in patients where no
swab test or CT scan were available. Timing of diagnosis of
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Table 1 Baseline patient, disease and operative characteristics stratified by SARS-CoV-2 status. Values are number
(proportion).
NoSARS-CoV-2 Peri-operative SARS-CoV-2 Recent SARS-CoV-2 Previous SARS-CoV-2 p value
n = 123,595 n = 2317 n = 953 n = 1148
Age; y
18–49 55,651 (45.0%) 968 (41.8%) 461 (48.4%) 480 (41.8%) <0.001
50–69 41,633 (33.7%) 696 (30.0%) 332 (34.8%) 470 (40.9%)
≥70 26,309 (21.3%) 653 (28.2%) 160 (16.8%) 198 (17.3%)
Missing 2 0 0 0
Sex
Female 66,495 (53.8%) 1228 (53.0%) 493 (51.7%) 611 (53.2%) 0.506
Male 57,096 (46.2%) 1089 (47.0%) 460 (48.3%) 537 (46.8%)
Missing 4 0 0 0
ASAphysical status
1–2 91,229 (73.8%) 1399 (60.4%) 635 (66.6%) 759 (66.1%) <0.001
3–5 32,323 (26.2%) 918 (39.6%) 318 (33.4%) 389 (33.9%)
Missing 43 0 0 0
Smoking
No 103,387 (83.9%) 1949 (84.3%) 845 (88.9%) 1017 (88.8%) <0.001
Yes 19,835 (16.1%) 364 (15.7%) 106 (11.1%) 128 (11.2%)
Missing 373 4 2 3
Respiratory comorbidity
No 111,785 (90.5%) 2026 (87.5%) 854 (89.6%) 1027 (89.5%) <0.001
Yes 11,713 (9.5%) 290 (12.5%) 99 (10.4%) 121 (10.5%)
Missing 97 1 0 0
Congestive heart failure
No 118,829 (96.2%) 2151 (92.8%) 907 (95.2%) 1079 (94.0%) <0.001
Yes 4738 (3.8%) 166 (7.2%) 46 (4.8%) 69 (6.0%)
Missing 28 0 0 0
Cerebral vascular disease
No 119,253 (96.5%) 2190 (94.5%) 922 (96.7%) 1103 (96.1%) <0.001
Yes 4314 (3.5%) 127 (5.5%) 31 (3.3%) 45 (3.9%)
Missing 28 0 0 0
Chronic kidney disease
No 120,475 (97.5%) 2179 (94.0%) 900 (94.4%) 1094 (95.3%) <0.001
Yes 3092 (2.5%) 138 (6.0%) 53 (5.6%) 54 (4.7%)
Missing 28 0 0 0
Ischaemic heart disease
No 112,894 (91.4%) 1995 (86.1%) 856 (89.8%) 1037 (90.3%) <0.001
Yes 10,673 (8.6%) 322 (13.9%) 97 (10.2%) 111 (9.7%)
Missing 28 0 0 0
Indication
Benigndisease 76,169 (61.6%) 1215 (52.4%) 561 (58.9%) 777 (67.7%) <0.001
Malignancy 23,251 (18.8%) 421 (18.2%) 211 (22.1%) 231 (20.1%)
Trauma 14,595 (11.8%) 436 (18.8%) 114 (12.0%) 91 (7.9%)
Obstetric 9577 (7.8%) 245 (10.6%) 67 (7.0%) 49 (4.3%)
Missing 3 0 0 0
(continued)
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SARS-CoV-2 in relation to the day of surgery was collected
as a categorical variable and further collapsed into one of
the following groups for analysis: no SARS-CoV-2; peri-
operative SARS-CoV-2 (diagnosed 7 days before to 30 days
after surgery); recent SARS-CoV-2 (diagnosed 1–6 weeks
before surgery); or previous SARS-CoV-2 (diagnosed
≥7 weeks before surgery). Data were also collected on the
presence or absence of respiratory or non-respiratory SARS-
CoV-2 symptoms if patients had a pre-operative SARS-CoV-
2 diagnosis. These were analysed as a combined group of
patients with asymptomatic infection or those with previous
symptoms now resolved, or patients with ongoing
symptoms. Symptoms in patients with a postoperative
SARS-CoV-2 diagnosis were not analysed as it was not
possible to separate these from standard postoperative
symptoms.
The primary outcome measure was VTE within 30 days
following surgery. Venous thromboembolism was defined
as either deep vein thrombosis (DVT) or pulmonary
embolism (PE). Deep vein thrombosis was defined as lower
limb DVT with or without symptoms that was proven
radiologically; and PE was defined as symptomatic PE,
radiologically proven or fatal PE discovered at post-mortem
or as judged by the clinical team. Secondary outcome
measures were postoperative pneumonia and mortality
within 30 days of surgery. Full study definitions can be
found in online Supporting Information Appendix S2.
Patients with data missing on VTE or SARS-CoV-2 status
and patients aged <18 y were excluded in the analysis. The
Chi-square test of independence was used to compare
groups in terms of categorical data. For the primary
outcome of VTE within 30 days of surgery, multivariable
logistic regression analysis was used to evaluate the
association of SARS-CoV-2 infection and VTE after surgery,
which was summarised using OR (95%CI). The model
included clinically relevant patient and operative factors in
order to adjust for covariates and reduce the risk of
confounding (baseline patient characteristics; pre-existing
comorbidities; operative factors). Multivariable adjusted
sub-group analyses were performed based on the main
analysis to define the patients in which SARS-CoV-2
infection was associated with additional risk of
postoperative VTE above the expected baseline risk of that
sub-group. This was done in the following four sub-groups:
major surgery; minor surgery; elective surgery; and
emergency surgery. A multivariable adjusted analysis was
also fitted for 30-day mortality as the outcome with VTE as
the main explanatory variable, using clinically relevant
patient and operative factors for adjustment. Analyses were
performedwith Stata SE version 16.1, (StataCorp, TX, USA).
Results
This analysis included 128,013 patients, from 1630 hospitals
across 115 countries. Baseline patient and operative
Table 1 (continued)
NoSARS-CoV-2 Peri-operative SARS-CoV-2 Recent SARS-CoV-2 Previous SARS-CoV-2 p value
n = 123,595 n = 2317 n = 953 n = 1148
Gradeof surgery
Minor 47,178 (38.2%) 695 (30.0%) 285 (29.9%) 439 (38.2%) <0.001
Major 76,392 (61.8%) 1622 (70.0%) 668 (70.1%) 709 (61.8%)
Missing 25 0 0 0
Urgency of surgery
Elective 87,117 (70.5%) 965 (41.6%) 604 (63.4%) 857 (74.7%) <0.001
Emergency 36,471 (29.5%) 1352 (58.4%) 349 (36.6%) 291 (25.3%)
Missing 7 0 0 0
Anaesthesia
Local/regional 34,508 (27.9%) 707 (30.5%) 222 (23.3%) 285 (24.8%) <0.001
General 89,035 (72.1%) 1609 (69.5%) 731 (76.7%) 863 (75.2%)
Missing 52 1 0 0
Country income
High 20,624 (66.9%) 399 (55.3%) 242 (38.4%) 121 (58.8%) <0.001
Uppermiddle 20,238 (16.4%) 636 (27.4%) 345 (36.2%) 352 (30.7%)
Lowmiddle/low 82,733 (16.7%) 1282 (17.2%) 366 (25.4%) 675 (10.5%)
Missing 0 0 0 0
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characteristics are shown in Table 1. Of these patients,
59,182 (46.2%) were men; 94,022 (73.5%) were ASA
physical status 1–2 and 20,433 (16.0%) were smokers. The
total number of patients who had a diagnosis of SARS-CoV-
2 infection was 4418 (3.5%). The timing of SARS-CoV-2
diagnosis in relation to the day of surgery was peri-
operative (7 days before to 30 days after surgery) for 2317
patients (1.8%); recent (1–6 weeks before surgery) for 953
patients (0.7%); and previous (≥7 weeks before surgery) for
1148 patients (0.9%; Fig. 1). Postoperative pneumonia was
chosen as the best fitting variable to represent more severe
SARS-CoV-2 infection. Proportionally, pneumonia occurred
most frequently in patients with peri-operative SARS-CoV-2
(497 patients, 21.5%), followed by recent SARS-CoV-2
patients (73, 7.7%). Patients with previous SARS-CoV-2 (19,
1.7%) and no SARS-CoV-2 diagnosis (2083, 1.7%) had the
same risk for postoperative pneumonia (Fig. 1). Compared
with patients who did not have SARS-CoV-2 infection,
patients with peri-operative SARS-CoV-2 were older (28.2%
vs. 21.3%, p < 0.001), ASA physical status 3–5 (39.6% vs.
26.2%, p < 0.001), underwent emergency surgery more
often (58.4% vs. 29.5%, p < 0.001) and had a greater
comorbid burden (Table 1). This trend was also present
when comparing patients without SARS-CoV-2 and those
with recent and previous infection (Table 1).
Overall, the rate of postoperative VTE was 0.6% (742/
128,013). Of these 742 patients, 44.3% (329) had a PE only,
47.5% (352) had a DVT only and 8.2% (61) had both. A full
description of the VTE event rates in relation to patient and
operative characteristics are reported in Table 2 and details
of PE and DVT by specialty can be found in online
Supporting Information Table S2. In adjusted analyses,
significant predictors of postoperative VTE were peri-
operative and recent SARS-CoV-2 infection; pneumonia;
age >50 y; ASA physical status 3–5; chronic kidney disease;
surgery for malignancy or trauma; major surgery;
emergency surgery; having a general anaesthetic; and
surgery performed in a country of upper-middle, low-
Figure 1 Flowdiagramof patients showing venous thromboembolism (VTE), pneumonia,mortality and SARS-CoV-2 infection.
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middle or low income (Fig. 2, detailed in online Supporting
Information Table S3). Pneumonia was strongly associated
with postoperative VTE, and obstetric procedures had a
lower rate of VTE when compared with benign (non-
obstetric, non-cancer) surgery (Fig. 2).
When compared against the main adjusted analysis
of all patients (Fig. 2), sub-group analysis of elective
surgery patients only demonstrated a stronger association
between peri-operative and recent SARS-CoV-2 infection
and VTE; this effect was diminished in patients having
emergency surgery (Fig. 3). Sub-group analysis in major
surgery demonstrated similar risk of postoperative VTE to
the main analysis in patients with peri-operative, recent or
previous SARS-CoV-2 infection, although there was no
significant effect in patients who had minor surgery
(Fig. 3).
In patients with pre-operative SARS-CoV-2 infection,
the presence of ongoing SARS-CoV-2 symptoms was
associated with increased incidence of VTE when compared
with patients without ongoing symptoms (Fig. 4). Ongoing
symptoms were associated with an overall 4.6% (17/406)
rate of postoperative VTE vs. 0.8% (21/2547) in patients who
were asymptomatic or whose symptoms had resolved. This
effect persisted even after stratifying patients by timing of
SARS-CoV-2 diagnosis (Fig. 4) and was observed even in
symptomatic patients with a SARS-CoV-2 diagnosis
Table 2 Unadjusted venous thromboembolism (VTE) rates





n = 742 p value
Age; y
18–49 57,368 (45.1%) 192 (25.9%) <0.001
50–69 42,852 (33.7%) 279 (37.6%)
≥70 27,049 (21.3%) 271 (36.5%)
Missing 2 0
Sex
Female 68,447 (53.8%) 380 (51.2%) 0.161
Male 58,820 (46.2%) 362 (48.8%)
Missing 4 0
ASAphysical status
1–2 93,699 (73.7%) 323 (43.5%) <0.001
3–5 33,529 (26.3%) 419 (56.5%)
Missing 43 0
Smoking
No 106,582 (84.0%) 616 (83.2%) 0.578
Yes 20,309 (16.0%) 124 (16.8%)
Missing 380 2
Respiratory comorbidity
No 115,067 (90.5%) 625 (84.2%) <0.001
Yes 12,106 (9.5%) 117 (15.8%)
Missing 98
Congestive heart failure
No 122,296 (96.1%) 670 (90.3%) <0.001
Yes 4947 (3.9%) 72 (9.7%)
Missing 28 0
Cerebral vascular disease
No 122,786 (96.5%) 682 (91.9%) <0.001
Yes 4457 (3.5%) 60 (8.1%)
Missing 28 0
Chronic kidney disease
No 123,962 (97.4%) 686 (92.5%) <0.001
Yes 3281 (2.6%) 56 (7.5%)
Missing 28 0
Ischaemic heart disease
No 116,174 (91.3%) 608 (81.9%) < 0.001
Yes 11069 (8.7%) 134 (18.1%)
Missing 28
Indication
Benigndisease 78,373 (61.6%) 349 (47.0%) <0.001
Malignancy 23,915 (18.8%) 199 (26.8%)
Trauma 15,066 (11.8%) 170 (22.9%)







n = 742 p value
Gradeof surgery
Minor 48,465 (38.1%) 132 (17.8%) <0.001
Major 78,781 (61.9%) 610 (82.2%)
Missing 25
Urgency of surgery
Elective 89,192 (70.1%) 351 (47.3%) <0.001
Emergency 38072 (29.9%) 391 (52.7%)
Missing 7
Anaesthesia
Regional/local 35,597 (28.0%) 125 (16.8%) <0.001
General 91,650 (72.0%) 617 (83.2%)
Missing 53
Country income
High 84,572 (66.4%) 484 (65.2%) 0.268
Uppermiddle 21,453 (16.9%) 118 (15.9%)
Lowmiddle/low 21,246 (16.7%) 140 (18.9%)
Missing 0
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≥7 weeks before surgery (5.7% in symptomatic patients vs.
0.7% in asymptomatic or resolved patients).
Overall, the rate of 30-day postoperative mortality was
1.7% (2195/128,009). When this was stratified by SARS-
CoV-2 infection and postoperative VTE, unadjusted
analyses demonstrated an incremental increase in mortality
rates with SARS-CoV-2 infection and VTE (Table 3). In
adjusted analyses, VTE was independently and strongly
associated (OR 5.4 (95%CI 4.4–6.8)) with 30-day mortality
(Table 4).
Discussion
This planned sub-study found that SARS-CoV-2 infection
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Figure 2 Forest plot of adjusted regressionmodel for factors associatedwith venous thromboembolism. Figures show the
reference value (Ref) andOR (95%CI) for the levels of each variable.
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of postoperative VTE in patients with peri-operative and
recent SARS-CoV-2 infection. In patients with pre-operative
SARS-CoV-2, ongoing symptoms were associated with an
increased rate of postoperative VTE, irrespective of how
long before surgery the diagnosis was made. Pneumonia
was strongly associated with postoperative VTE, possibly
due to a combination of SARS-CoV-2-induced pneumonitis
and a more difficult postoperative period involving
infection, increased disease burden and greater immobility.
Mortality was highest in patients with SARS-CoV-2 infection
and VTE, and in adjusted analyses, SARS-CoV-2 and VTE
were both independently associated with 30-day mortality.
However, these results were limited by a lack of information
on pre-operative anticoagulant use and postoperative VTE
prophylactic regimens.
Overall, emergency surgery patients have a higher rate
of postoperative VTE. However, sub-group analysis
demonstrated that in elective patients, there was a greater
additional VTE risk in patients with SARS-CoV-2 when
compared with patients with no SARS-CoV-2. This
additional risk was not as pronounced in emergency
surgery patients. Without data on any differences in the VTE
prophylaxis and anticoagulation regimes between the
elective and emergency surgery patients, no firm
conclusions can be drawn. However, it is possible that this
could be a consequence of the greater number of VTE risk-
factors associated with emergency surgery, resulting in any
additional risk from SARS-CoV-2 infection having less of an
impact on the overall risk of postoperative VTE. This
translates into a disproportionately increased risk in patients
Previous (≥ 7 weeks) SARS-CoV-2
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(a)
(b)
Figure 3 Adjusted sub-group analysis for venous thromboembolism in (A) elective and emergency patients and (B)major and
minor surgery patients. Sub-group analyses are adjusted for the following variables: pneumonia; age; sex; ASAphysical status;
smoker; respiratory comorbidities; congestive heart failure; cerebral vascular disease; chronic kidney disease; ischaemic heart
disease; indication; grade; urgency; anaesthesia; and country income. Full details can be found in online Supporting
Information Tables S4 to S7. Figures show the reference value (Ref) andOR (95%CI) for the levels of each variable.
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undergoing elective surgery. Sub-group analysis also
demonstrated greater additional risk in patients
undergoing major surgery. This is most likely due to the
smaller proportion of patients with peri-operative SARS-
CoV-2 infection having minor elective surgery during the
ongoing pandemic. Overall, minor surgery patients were
exposed to fewer of the risk-factors for VTE, and baseline
VTE rate was low. Concurrent SARS-CoV-2 infection was not
associatedwith a significant increase in additional risk.
There have been numerous studies describing the
elevated rates of VTE in medical patients who are
hospitalised with COVID-19 on the ward or in the ICU, and
results are pending for a number of ongoing randomised
controlled trials investigating VTE prophylaxis and
therapeutic protocols. To date, some studies describe
increased bleeding risk with therapeutic (high) dosing of
pharmacological VTE prophylaxis [10], and interim analyses
of several randomised controlled trials report unfavourable
outcomes with therapeutic pharmacological prophylaxis in
patients with severe COVID-19 (i.e. admitted to ICU).
However, improved outcomes and a reduced requirement
for organ support has been seen in patients with moderate
severity of COVID-19 (i.e. hospitalised) who receive
therapeutic anticoagulation [15]. This highlights the
challenge of anticoagulating patients with COVID-19, which
is likely to be evenmore complex in patients having surgery,
although our results suggest that anticoagulation in patients
with previous, recent or peri-operative SARS-CoV-2
infectionmay be an important consideration.
Surgical patients represent a uniquely different cohort.
Unlike medical patients, the primary reason for hospital
admission for surgical patients is rarely due to COVID-19,
and other co-existing primary pathology requiring surgical
intervention is also present. Surgical patients undergo an
operative procedure which artificially produces a wound
that increases the risk of intra-operative and postoperative
bleeding and sets in motion a cascade of inflammatory
responses known to alter haemodynamics and coagulation.
Paired with this, surgical patients often experience a period
of reduced mobility immediately before, during and after
Figure 4 Venous thromboembolism (VTE) and 30-daymortality in patients with pre-operative SARS-CoV-2 by presence or
absence of COVID-19 symptoms.
Table 3 Rate of 30-day mortality stratified by SARS-CoV-2 and venous thromboembolism (VTE) status. Values are fraction
(proportion)
NoVTE VTE p value
All patients 2047/127,271 1.6% 148/742 20.0% < 0.001
NoSARS-CoV-2 infection 1728/122,929 1.4% 117/666 17.6% < 0.001
Any SARS-CoV-2 infection 319/4342 7.4% 31/76 40.8% < 0.001
Peri-operative SARS-CoV-2 236/2267 10.4% 20/50 40.0% < 0.001
Recent SARS-CoV-2 60/938 6.4% 10/15 66.7% < 0.001
Previous SARS-CoV-2 23/1137 2.0% 1/11 9.1% 0.103
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Table 4 Adjusted regressionmodel for predictors for 30-daymortality. Values are fraction (proportion) orOR (95%CI)
Mortality OR (95%CI) p value
VTE status
NoVTE 2047/127,267 (1.6%)
VTE 594/742 (20.0%) 5.42 (4.36–6.75) <0.001
SARS-CoV-2 status
NoSARS-CoV-2 1845/123,591 (1.5%)
Peri-operative SARS-CoV-2 256/2317 (11.1%) 2.38 (2.00–2.82) <0.001
Recent SARS-CoV-2 70/953 (7.4%) 2.78 (2.09–3.71) <0.001
Previous SARS-CoV-2 24/1148 (2.1%) 1.13 (0.72–1.76) 0.597
Pneumonia
No 1666/125,337 (1.3%)
Yes 529/2672 (19.8%) 5.28 (4.65–6.00) <0.001
Age; y
18–49 429/57,557 (0.8%)
50–69 757/43,130 (1.8%) 1.62 (1.41–1.86) <0.001
≥70 1009/27,320 (3.7%) 2.67 (2.31–3.10) <0.001
Sex
Female 956/68,825 (1.4%)
Male 1239/59,180 (2.1%) 1.06 (0.96–1.16) 0.269
ASAphysical status
1–2 543/94,020 (0.6%)
3–5 1651/33,946 (4.9%) 4.32 (3.84–4.86) <0.001
Smoking
No 1796/105,399 (1.7%)
Yes 387/20,045 (1.9%) 1.16 (1.02–1.32) 0.021
Respiratory comorbidities
No 1843/115,688 (1.6%)
Yes 349/12,223 (2.9%) 0.95 (0.83–1.08) 0.410
Congestive heart failure
No 1859/122,962 (1.5%)
Yes 336/5019 (6.7%) 1.54 (1.34–1.78) < 0.001
Cerebral vascular disease
No 1940/123,465 (1.6%)
Yes 255/4516 (5.7%) 1.37 (1.18–1.60) < 0.001
Chronic kidney disease
No 1884/124,644 (1.5%)
Yes 311/3337 (9.3%) 2.32 (2.00–2.69) <0.001
Ischaemic heart disease
No 1677/116,778 (1.4%)
Yes 518/11,203 (4.6%) 1.01 (0.90–1.14) 0.842
Indication
Benign 1174/78,720 (1.5%)
Malignancy 569/24,112 (2.4%) 1.90 (1.68–2.14) <0.001
Trauma 413/15,236 (2.7%) 0.91 (0.80–1.04) 0.160
Obstetric 39/9938 (0.4%) 0.39 (0.27–0.55) <0.001
(continued)
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their operation, even for the young and normally fit and
healthy. Furthermore, elective surgical patients are a group
that can have a planned hospital admission, often following
a period of self-isolation with reducedmobility, andmany of
these patients will have peri-operative mechanical
ventilation. These differences in patient physiology and
exposure signify a need to define VTE risk specifically in
surgical patients, not only to provide a baseline
understanding of peri-operative risk in the setting of
COVID-19, but also to work towards constructing future VTE
regimens specifically suited to surgical patients with active
or prior SARS-CoV-2 infection.
This study has several limitations. First, information on
postoperative VTE prophylaxis regimens (mechanical and
pharmacological) and pre-existing anticoagulation for
specific patient comorbidities associated with prophylaxis
(e.g. atrial fibrillation) were not collected as part of this
study. During the period of study (October 2020), patients
with known SARS-CoV-2 infection might have already
empirically received enhanced VTE prophylaxis based on
earlier reports associating COVID-19 and an increased risk
of VTE. The present study data report outcomes from VTE
care and prophylaxis which were deemed acceptable and
appropriate for each individual patient in participating
departments from each country at the time of the study. Any
additional risk could be interpreted as risk above prevailing
VTE protocols and practice. Second, this study did not
include patients who had an asymptomatic VTE diagnosed
as a result of screening. Though there are reports of VTE
screening being carried out in high-risk patient groups, the
clinical relevance of asymptomatic, distal DVT is uncertain
and could lead to overdiagnosis and skewed results [1].
Venous thromboembolism diagnoses made in this study
were likely due to symptomatic presentation or a high index
of clinical suspicion leading to radiological confirmation,
and we believe that the incidence of VTE in this study is
representative of the true, clinically relevant figure. Third,
the rate of SARS-CoV-2 infection in October of 2020 and the
overall incidence of VTE in surgical patients were both
relatively low. Despite the large number of patients in this
study, some sub-group analyses have resulted in small
patient samples, and these should be interpreted with
caution. Finally, there exists the possibility that some
patients who had SARS-CoV-2 infection never attained a
formal diagnosis and were therefore classified as no SARS-
CoV-2. This most likely occurred in patients with
asymptomatic infection. This study reported a high
proportion of patients with asymptomatic infection which
provides some reassurance that these cases were
appropriately counted. While asymptomatic patients could
have been misclassified as no SARS-CoV-2, this
misclassification would have resulted in an underestimation
of the overall difference in VTE between groups, and our
estimate could be considered conservative.
Despite this study’s limitations, recent and peri-
operative SARS-CoV-2 infection may be an independent
risk-factor for postoperative VTE, and increased awareness
and surveillance should be considered. At a minimum, we
suggest close adherence to routine standard VTE
prophylaxis for surgical patients, including the use of
Table 4 (continued)
Mortality OR (95%CI) p value
Gradeof surgery
Minor 388/48,596 (0.8%)
Major 1807/79,388 (2.3%) 1.80 (1.59–2.03) <0.001
Urgency of surgery
Elective 666/89,540 (0.7%)
Emergency 1535/38,462 (4.0%) 5.62 (5.03–6.27) <0.001
Anaesthetic
Local/regional 306/35,721 (0.9%)
General 1888/92,235 (2.1%) 1.90 (1.65–2.18) <0.001
Country income
High 1196/85,055 (1.4%)
Uppermiddle 463/21,569 (2.2%) 2.43 (2.15–2.75) <0.001
Lowermiddle/low 536/21,385 (2.5%) 4.73 (4.17–5.37) <0.001
VTE, venous thromboembolism.
Peri-operative SARS-CoV-2, 7 days before to 30 days after surgery; recent SARS-CoV-2, 1–6 weeks before surgery; previous SARS-CoV-
2, ≥ 7 weeks before surgery.
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pharmacological agents when bleeding risk is minimal, and
increased vigilance with a heightened index of suspicion
and a lower threshold for definitive diagnostic testing in
patients presentingwith signs of VTE. Routine postoperative
care of surgical patients should include interventions to
reduce VTE risk in general, and further research is needed to
define the optimal protocols for VTE prophylaxis and
treatment for surgical patients in the setting of SARS-CoV-2
infection.
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